Volume 67, Issue 2, Pages (February 2015)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

Volume 69, Issue 5, Pages (May 2016)

Volume 61, Issue 6, Pages (June 2012)

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 5, Pages (May 2016)

Volume 53, Issue 5, Pages (May 2008)

Volume 68, Issue 1, Pages (July 2015)

Volume 52, Issue 3, Pages (September 2007)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 70, Issue 5, Pages (November 2016)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 72, Issue 5, Pages (November 2017)

Volume 63, Issue 2, Pages (February 2013)

Volume 68, Issue 1, Pages (July 2015)

Volume 189, Issue 1, Pages S45-S50 (January 2013)

Volume 54, Issue 4, Pages (October 2008)

Volume 65, Issue 1, Pages (January 2014)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Prostate Cancer Management: What Does the Future Hold?

Volume 66, Issue 3, Pages (September 2014)

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Yuanshan Cui, Yong Zhang European Urology

Volume 53, Issue 2, Pages (February 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 72, Issue 1, Pages (July 2017)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 67, Issue 1, Pages (January 2015)

Volume 73, Issue 2, Pages (February 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

Risk Factors for the Development of Bone Metastases in Prostate Cancer

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

The Importance of Testosterone Control in Prostate Cancer

Optimal Testosterone Control and Eligard®

Neal Shore European Urology Supplements

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 72, Issue 2, Pages (August 2017)

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 70, Issue 1, Pages (July 2016)

Volume 71, Issue 4, Pages (April 2017)

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Improving Flexibility and Quality of Life for Your Patients: A Must?

Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid Theresa A. Guise,

Highlighting Unmet Needs: Real Patients, Difficult Choices

Volume 53, Issue 6, Pages (June 2008)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 67, Issue 2, Pages 334-341 (February 2015) Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer Evan Y. Yu, Robert H. Getzenberg, Christopher C. Coss, Marc M. Gittelman, Thomas Keane, Ronald Tutrone, Laurence Belkoff, Robert Given, Joel Bass, Franklin Chu, Michael Gambla, Franklin Gaylis, James Bailen, Michael L. Hancock, Jordan Smith, James T. Dalton, Mitchell S. Steiner European Urology Volume 67, Issue 2, Pages 334-341 (February 2015) DOI: 10.1016/j.eururo.2014.06.011 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Consolidated Standards of Reporting Trials diagram describing the G200705 clinical trial. European Urology 2015 67, 334-341DOI: (10.1016/j.eururo.2014.06.011) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 2 Measurements of total testosterone and prostate-specific antigen (PSA) during the course of the study in days. (A) Absolute total testosterone and (B) percentage PSA decline measurements in the intention-to-treat population throughout the course of the study. European Urology 2015 67, 334-341DOI: (10.1016/j.eururo.2014.06.011) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 3 Free testosterone (T) levels. (A) Median free T (nanograms per deciliter) and (B) the percentage of free T (free T/total T) over the course of the study in the intention-to-treat population. European Urology 2015 67, 334-341DOI: (10.1016/j.eururo.2014.06.011) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 4 Percentage of patients who experienced hot flashes while on treatment. The occurrence of hot flashes during the specified time periods between study visits are plotted as a percentage of the patients experiencing them. European Urology 2015 67, 334-341DOI: (10.1016/j.eururo.2014.06.011) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 5 The bone turnover biomarkers (A) c-terminal telopeptide (CTX) and (B) bone-specific alkaline phosphatase (BSAP) are presented as the percentage change from baseline to day 120. These values represent only the castrate population because the patients who did not reach castrate testosterone levels were discontinued on the study on day 60. European Urology 2015 67, 334-341DOI: (10.1016/j.eururo.2014.06.011) Copyright © 2014 European Association of Urology Terms and Conditions